FDA Grants Priority Review to Enhertu for HER2‑Positive Early Breast Cancer With Residual Disease
- March 11, 2026
Two Intellia Clinical Trials Released by the FDA
Gene Therapy Setback: REGENXBIO’s RGX-121 Faces Regulatory Hurdles in Ultra-Rare Disease Treatment
Serina Therapeutics Begins First-in-Patient Dosing in Phase 1b Trial of SER‑252 for Advanced Parkinson’s Disease
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
Patient safety isn't just a priority- it's a promise. During Patient Safety Awareness Week, we reaffirm our commitment to protecting every patient, every time. Because every voice matters, every step counts, and every patient deserves care that is safe, compassionate, and unwavering. 💜 🤗 🫂 #HealthcareSafety #QualityCare #PatientWorthy
For many people living with a rare disease, symptoms don’t always follow a straight path. Periods of stability or improvement can sometimes be followed by the return or worsening of symptoms, bringing new uncertainty and challenges. Understanding these patterns is an important part of recognizing how complex rare diseases can be and why ongoing awareness, research, and support are so important.
#RareWordOfTheWeek #RareDisease #RareDiseaseAwareness #PatientWorthy
We had the pleasure of meeting Monica and Kendall at Rare Disease Week in DC! At the young age of 2 Kendall started showing painful signs of Myasthenia Gravis (MG). She was given a life changing diagnoses of MG at the age of three. Kendall is an amazing, strong, and brave young advocate. Kendall was one of the youth advocates that spoke to the members of congress for change. It was inspiring to meet and hear the voice of such a young advocate looking for change. Thank you for taking the time to chat with us. We look forward to seeing more amazing advocacy work from you in the future. Keep shining we see you!
#raredc2026 #RareDiseaseWeek #PatientWorthy #MG #myastheniagravis
